Skip to Content

Adjuvant Osimertinib – New Standard of Care for Patients with Resected EGFR-mutated NSCLC

Results from ASCO 23 provide confidence that adjuvant osimertinib should be considered the standard of care for patients with resected EGFRm stage IB–IIIA NSCLC.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top